Pfizer (PFE)

Explore how differences in bond type, risk, and income potential set these two popular ETFs apart for investors.

The weight loss drug market may reach almost $100 billion in a few years.

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s why.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks?

What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

The healthcare giant has been investing heavily in its future growth.

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers.

Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries.

Start with the drug pipeline when researching pharma stocks to own.

ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries.

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing

Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range.

These stocks have been struggling in recent years, but they are safer investments than they appear to be at first glance.

As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue, in 2023, the New Brunswick-based giant has shed its "band-aid and baby powder" image to emerge as a high-octane, pure-play healthcare powerhouse. [...]

The choice is based on more than just the dividend payout.

The company has increased its payouts over the past five years despite significant challenges.

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total consideration of up to $5 billion. This strategic maneuver, consisting of $3.15 billion in upfront cash and